Preclinical News and Research

RSS

Miniature spectroscopic instruments and software to look at changes that occur within the cells and tissue of the brain

When molecules in cells are stimulated by light, they respond by becoming excited and re-emitting light of varying colors (fluorescence) that can be captured and measured by highly sensitive optical equipment.

2 Aug 2004

Research collaboration to discover novel oral drugs for the treatment of viral infections

Sunesis Pharmaceuticals, Inc. and Merck & Co., Inc. have announced that they have entered into a multi-year research collaboration to discover novel oral drugs for the treatment of viral infections.

29 Jul 2004

Transplanted cells are capable of surviving in the brain of immunosuppressed stroked rats

Human neural stem cells proprietary to StemCells, Inc. have been used in a Stanford University study in a preclinical stroke model.

29 Jul 2004

Australian collaboration to produce cancer immunotherapy vaccines

A Brisbane based biomedical company, Tissue Therapies Limited (TIS) and the Queensland Institute of Medical Research (QIMR) have agreed on the terms of a new collaboration aimed at developing Tissue Therapies' VitroGro® cell growth technology as a platform to produce cancer immunotherapy vaccines.

21 Jul 2004

Radiance FN/Radiesse injectable implant material appears effective and well tolerated by patients undergoing facial soft tissue augmentation

An article in the July/August issue of the Archives of Facial Plastic Surgery reports that the use of Radiance FN/Radiesse injectable implant material appears effective and well tolerated by patients undergoing facial soft tissue augmentation, and patient satisfaction with treatment is high.

20 Jul 2004

CancerVax may increase the survival of patients with advanced stage non-small-cell lung cancer

CancerVax Corporation has announced that its wholly owned subsidiaries, Tarcanta, Inc., and Tarcanta, Ltd. (Ireland), have obtained the exclusive rights to complete the clinical development of three specific active immunotherapeutic (SAI) product candidates that target the epidermal growth factor receptor (EGFR) signaling pathway for the treatment of cancer.

19 Jul 2004

Fall in the number of confirmed cases of Haemophilus influenzae type b (Hib) disease

A Health Protection Agency study has shown a sharp fall in the number of confirmed cases of Haemophilus influenzae type b (Hib) disease following the introduction of a Department of Health booster campaign, the Agency’s Board heard today.

2 Jul 2004

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for regulatory approval of exenatide.

1 Jul 2004

Alcon updates filing status of RETAANE® new drug application

Alcon, Inc. has announced that it has filed the second portion of its “rolling” New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for RETAANE® 15mg (anecortave acetate for depot suspension)

30 Jun 2004

Duloxetine reduces stress urinary incontinence and improves quality of life for women

Data presented today at the 3rd International Consultation on Incontinence, provide evidence for the efficacy of duloxetine, an investigational agent for the treatment of women with stress urinary incontinence (SUI).

29 Jun 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Gene chip technology can detect one of the commonest cystic fibrosis (CF) genetic mutations with 100% accuracy

A single genetic test that is capable of detecting all mutations involved in the development of cystic fibrosis could be just a few years away, the 20th annual conference of the European Society of Human Reproduction and Embryology heard today (Monday 28 June).

28 Jun 2004

Paclitaxel analog kills more cancer cells than natural product

Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.

21 Jun 2004

Early patient response to Forteo in postmenopausal women with osteoporosis

Changes in markers of bone remodeling after one month of treatment with FORTEO® (teriparatide [rDNA origin] injection) may provide important early evidence of treatment response, according to new data presented today at the 86th Annual Meeting of The Endocrine Society (ENDO).

17 Jun 2004

Ultrasound technology to treat cancer

Ultrasound scans might be most familiar for getting a peek at a developing fetus, but the technology could also be used to treat cancer. A partnership between UC Davis, Siemens Medical Systems and ImaRx Inc., funded by a National Cancer Institute grant, will study ways to deliver drugs to tumors using focused ultrasound.

17 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

Compared to the snapshot views of the immune system from tumor biopsies or blood assays, this whole body imaging allows scientists to track how the immune response changes, and the tumor or infection responds, throughout the different phases of immune response and over long periods of time.

15 Jun 2004

$2.5 billion will be invested in the search for type 1 diabetes cure for over next 5 years

The Juvenile Diabetes Research Foundation (JDRF), the world's leading charitable funder of research leading to a cure of type 1 diabetes and its complications, held the Global Diabetes Research Forum today as part of its annual meeting in Washington, DC.

14 Jun 2004

Outsourcing the way to control spiraling R&D budgets in drug industry

Companies developing new drugs for the global market must deal with the rising costs of the R&D process – and outsourcing may well be the best route. That's the verdict of Dr Faiz Kermani, a specialist in outsourcing and research development for the pharmaceutical industry.